Abstract
Objective of this review is a systematic analysis of the data available in the current literature on the efficacy and safety of progestogens for the prevention of atypical endometrial hyperplasia (EH) in patients of reproductive age. EH is an excessive proliferation that results in increased volume and changes in endometrial tissue architectonics with an increase in the endometrial glands to stroma ratio of more than 1:1. This review will consider the use of progestogens for the prevention of (EH) based on evidence-based scientific evidence over the past 5 years. The expansion of the range of effective treatment options allows the adaptation of treatment to the needs of patients and offers a personalized approach to their management. Progestogens are an effective and safe method for the prevention of atypical hyperplasia, with a wide range of therapeutic benefits associated with reliable favorable fertility prognosis, especially in young women.
Subject
Obstetrics and Gynecology
Reference45 articles.
1. Horn LC, Schnurrbusch U, Bilek K, et al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 2004;14:348-53.
2. Scully RE, Bonfiglio TA, Kurman RJ, et al. Uterine corpus. In: Histological Typing of Female Genital Tract Tumours (2nd edn). New York: Springer-Verlag, 1994; p. 13.
3. Silverberg SG, Mutter GL, Kurman RJ, et al. Tumors of the uterine corpus: epithelial tumors and related lesions. In: WHO Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003; p. 221-32.
4. Emons G, Beckmann MW, Schmidt D, et al. New who classifi cation of endometrial hyperplasias. Geburtshilfe Frauenheilkd. 2015;75:135-6.
5. Antonsen SL, Ulrich L, Hogdall C. Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. Gynecol Oncol. 2012;125:124-8.